medRxiv : the preprint server for health sciences
July 14, 2026
Ali J Zarrabi, Tanja Mletzko, George H. Grant et al.
Demoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization. To date, PAT has not been studied among people living with both demoralization and chronic pain nor has it...
Psychotherapy
January 13, 2025
Roman Palitsky, Jessica L Maples-Keller, Caroline Peacock et al.
13 citations
Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is a priority, but psychotherapeutic protocol components of PAT have been subjected to little rigorous research. This study was designed to assess protocol components in a trial of PAT. The Enhanced Critical Incident Technique (E-CIT) was used to...
Psychedelics.
December 17, 2024
Zachary Bosshardt, Jessica L Maples-Keller, Deanna M Kaplan et al.
Social attitudes, policy, and perceptions of psychedelics are currently undergoing considerable change. Growing public salience of psychedelics has been accompanied by the emergence of conferences focused on psychedelic education and dialogue. Attendees at such events compose an important group of stakeholders in psychedelic science and practice; their views of psychedelics can be valuable for...
Journal of Psychopharmacology
July 31, 2024
Roman Palitsky, Deanna M Kaplan, John Perna et al.
32 citations
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A...
JAMA
August 31, 2023
Charles L. Raison, Gerard Sanacora, Joshua Woolley et al.
493 citations
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...